A COMPARATIVE-STUDY OF THE ACTIONS OF TAMOXIFEN, ESTROGEN AND PROGESTERONE IN THE OVARIECTOMIZED RAT

被引:84
作者
KALU, DN
SALERNO, E
LIU, CC
ECHON, R
RAY, M
GARZAZAPTA, M
HOLLIS, BW
机构
[1] UNIV TEXAS,HLTH SCI CTR,DEPT OBSTET & GYNECOL,SAN ANTONIO,TX 78284
[2] AMER LAKE VET ADM MED CTR,TACOMA,WA
[3] UNIV WASHINGTON HOSP,DEPT MED,SEATTLE,WA 98195
[4] MED UNIV S CAROLINA,CHARLESTON,SC 29425
来源
BONE AND MINERAL | 1991年 / 15卷 / 02期
关键词
OVARIECTOMY; ESTROGEN; TAMOXIFEN; BONE LOSS;
D O I
10.1016/0169-6009(91)90002-H
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study was undertaken to examine the separate and combined effects of tamoxifen (T), estrogen (E2) and progesterone (P) treatment on ovariectomized (Ooph) rats. The animals were treated for 40 days. Ovariectomy reduced cancellous bone volume at the proximal tibia by 50%. Estradiol treatment completely prevented the bone loss and further increased bone volume 77% over the level for the control group. Tamoxifen also prevented the ovariectomy induced bone loss, but significantly reduced the increase in cancellous bone induced by estradiol. In the ovariectomized rats, cancellous bone apposition rate increased 23%. This increase was suppressed 63% by estradiol, and only 18% by tamoxifen. Tamoxifen significantly suppressed the inhibitory effect of estradiol on cancellous bone apposition rate. In contrast, the effect of progesterone treatment was only marginal. Our findings indicate that the action of tamoxifen on bone is influenced by the ambient level of circulating estradiol, such that in estrogen deficiency, tamoxifen has a weak estrogen agonist action on bone, and in the presence of estrogen it has anti-estrogen actions, with the dose level and mode of administration employed. These conclusions have implications for the use of tamoxifen in the treatment of pre- and postmenopausal women.
引用
收藏
页码:109 / 123
页数:15
相关论文
共 43 条
[31]  
MARCH CM, 1981, OBSTET GYNECOL, V58, P10
[32]   INFLUENCE OF PREOVULATORY ESTRADIOL CONCENTRATION ON DIURNAL AND PULSATILE PROLACTIN SECRETION PATTERNS [J].
MARSHALL, LA ;
MARTIN, MC ;
LEONG, S ;
JAFFE, RB .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1988, 159 (06) :1558-1563
[33]  
MILAN RH, 1986, REPRODUCTIVE ENDOCRI, P652
[34]   TREATMENT OF POST-MENOPAUSAL OSTEOPOROSIS [J].
NORDIN, BEC .
DRUGS, 1979, 18 (06) :484-492
[35]   PROGESTERONE AS A BONE-TROPHIC HORMONE [J].
PRIOR, JC .
ENDOCRINE REVIEWS, 1990, 11 (02) :386-398
[36]   THE EFFECT OF PERCUTANEOUS ESTRADIOL AND NATURAL PROGESTERONE ON POSTMENOPAUSAL BONE LOSS [J].
RIIS, BJ ;
THOMSEN, K ;
STROM, V ;
CHRISTIANSEN, C .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1987, 156 (01) :61-65
[37]  
Snedecor G.W., 1980, STAT METHODS
[38]   TAMOXIFEN IS A POTENT PURE ANTI-OESTROGEN IN CHICK OVIDUCT [J].
SUTHERLAND, R ;
MESTER, J ;
BAULIEU, EE .
NATURE, 1977, 267 (5610) :434-435
[39]   STRUCTURE-ACTIVITY RELATIONSHIPS OF ANTI-OESTROGENS WITH REGARD TO INTERACTION WITH 17BETA-OESTRADIOL IN MOUSE UTERUS AND VAGINA [J].
TERENIUS, L .
ACTA ENDOCRINOLOGICA, 1971, 66 (03) :431-&
[40]   EFFECTS OF TAMOXIFEN ON SPINAL BONE-DENSITY IN WOMEN WITH BREAST-CANCER [J].
TURKEN, S ;
SIRIS, E ;
SELDIN, D ;
FLASTER, E ;
HYMAN, G ;
LINDSAY, R .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (14) :1086-1088